EP0533895A1 - Novel quinolones, method of preparation and pharmaceutical compositions containing them - Google Patents

Novel quinolones, method of preparation and pharmaceutical compositions containing them

Info

Publication number
EP0533895A1
EP0533895A1 EP19920909453 EP92909453A EP0533895A1 EP 0533895 A1 EP0533895 A1 EP 0533895A1 EP 19920909453 EP19920909453 EP 19920909453 EP 92909453 A EP92909453 A EP 92909453A EP 0533895 A1 EP0533895 A1 EP 0533895A1
Authority
EP
European Patent Office
Prior art keywords
radical
acid
general formula
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920909453
Other languages
German (de)
French (fr)
Inventor
Claude Perrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bouchara SA
Original Assignee
Bouchara SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bouchara SA filed Critical Bouchara SA
Publication of EP0533895A1 publication Critical patent/EP0533895A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the subject of the present invention is new quinolones and more particularly quinolones substituted by a piperidine cycle.
  • Z represents an amino radical
  • RI represents a radical (lower alkyl optionally hydroxylated)
  • an acyl radical derived from an organic carboxylic acid, from an aicoyl carbonic acid, or from an alkylsulphonic acid, or an arylamino carbonyl radical of shape :
  • Ar represents a mono or bicyclic aromatic radical, optionally substituted by one, two or three substituents chosen from lower alkyl, halogens and trifluoromethyl.
  • X represents oxygen or sulfur.
  • RI represents hydrogen or a linear or branched lower alkyl radical, optionally substituted by a hydroxyl.
  • Ac represents the remainder of an aliphatic, aromatic or cyclanic carboxylic acid having from 1 to 10 carbon atoms, the remainder of an alkylcarbonic acid or else the remainder of an alkylsulfonic acid optionally substituted by a hydroxyl or a trifluoromethyl radical .
  • REPLACEMENT SHEET in which X represents oxygen or sulfur.
  • W is a C-H or N group
  • B is hydrogen or an aromatic structure with 5 or 6 links.
  • Z is hydrogen, a lower alkyl radical, a trifluoromethyl radical or a halogen. and p is 1.2 or 3
  • the compounds for which ZR1 is a ureido function are those which are currently preferred.
  • the compounds according to the invention can be salified by adding a mineral or organic base.
  • the main salts which can be used are those of alkali metals, alkaline earth metals, ammonium, iron, aluminum, the alkylamine salts, the hydroxyalkylamine salts, the phenylalkylamine salts, the pyridylalkylamine salts, the salts of cyclanylamines, dicyclanylalkoylamine salts ...
  • the sodium, lithium, ammonium, N.methylglucamine and tromethanol salts are those presently preferred.
  • R ⁇ rreepprréésseennttee ddee ll'hydrogen, a lower alkyl radical or a lower radical (hydroxyalkyl).
  • the compounds according to the invention have very marked anti-bacterial properties, in particular against Gram positive bacteria.
  • REPLACEMENT SHEETs can therefore be used effectively as drugs for bacterial infections of the digestive tract for the treatment of bacterial dysentry, travelers' diarrhea, or intestinal infections. They can also be used topically for the treatment of eye infections or ear canal infections.
  • the compounds according to the invention will be used in the form of pharmaceutical compositions in which the active principle of general formula I or one of its salts, is added or mixed with an excipient or an inert non-toxic pharmaceutically acceptable vehicle.
  • the most suitable pharmaceutical forms are those intended for administration by the digestive route such as oral solutions or suspensions, granules, capsules, bare or coated tablets, sugar-coated tablets, sachets of powdered flavored or not, sweetened or not, pills or cachets. Solutions, creams, ointments, salts can also be used for topical application as an external antibacterial agent.
  • the average dosage depends mainly on the severity of the infection and the sensitivity of the microbial germ to the antibacterial agent.
  • the unit dosage ranges from 100 to 600 mg per dose.
  • the daily dosage ranges from 200 to 1200 mg divided into 2 to 4 doses.
  • the invention also relates to a process for obtaining the compounds of general formula I which consists in reacting 6-fluoro 7-jchloro 1-ethyl 4-oxo 1, 4-dihydroquinoleine 3-carboxylic acid.
  • formula II
  • the invention also relates to a process for converting the amino compound of formula III into urea or thiourea which consists in subjecting the compound of formula NI to the action of an isocyanate or aryl isothiocyanate of formula
  • the crystals formed are separated, which are drained and which are crystallized from a mixture of dimethylfor arnide-ethanol.
  • REPLACEMENT SHEET 2 The measurement of the minimum inhibitory concentrations was made by a microdilution technique in liquid medium (Mueller-Hinton broth) in a volume of 100 ⁇ l and for a concentration range from 128 to 0.06 mg L, prepared at from a stock solution of antibiotic titrated 512 mg / L. The preparation of these stock solutions carried out according to the manufacturer's instructions varied according to the molecules.
  • the inoculation is done by adding to each capsule 10 ⁇ l of a dilution in physiological water of an 18 H broth in brain heart broth such that each cup contains approximately 10 bacteria / ml.
  • the minimum inhibitory concentration is read as the first concentration of non-culture-giving antibiotic, macroscopically visible after 18 H of incubation at 37 °.
  • the minimum bactericidal concentration (CMB) is the first concentration for which the bactericidal effect • $ 0.01 of surviving germs was obtained.
  • Example II The compound of Example II was found to be the most active. In particular with regard to Staphycococcus aureus:
  • the MIC is 0.2 mcg / ml
  • the CMB is 0.5 mcg / ml.
  • the MIC is 8 mcg / ml
  • the CMB is 8 mcg / ml

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte au domaine de la chimie organique et plus précisément à celui de la chimie thérapeutique. Elle a plus particulièrement pour objet les nouveaux acides 6-fluoro 7-pipéridinyl quinolone-3 carboxylique de formule générale (I) dans laquelle Z représente un radical amino, et R2 un radical (alcoyle inférieur éventuellement hydroxylé), un radical acyle dérivé d'un acide organique carboxylique, d'un acide alcoyl carbonique, ou d'un acide alcoylsulfonique, ou un radical arylamino carboxyle de la forme (a) dans laquelle Ar représente un radical aromatique, mono ou bicyclique, éventuellement substitué par un, deux ou trois substituants choisis parmi les alcoyle inférieurs, les halogènes et le trifluorométhyle, et X représente de l'oxygène ou du soufre, ainsi que leurs sels d'addition. Les composés de formule générale (I) sont des principes actifs de médicaments antibactériens.The invention relates to the field of organic chemistry and more specifically to that of therapeutic chemistry. It more particularly relates to the new 6-fluoro 7-piperidinyl quinolone-3 carboxylic acids of general formula (I) in which Z represents an amino radical, and R2 a radical (lower alkyl optionally hydroxylated), an acyl radical derived from an organic carboxylic acid, an alkyl carbonic acid, or an alkylsulphonic acid, or an arylamino carboxyl radical of the form (a) in which Ar represents an aromatic radical, mono or bicyclic, optionally substituted by one, two or three substituents chosen from lower alkyl, halogens and trifluoromethyl, and X represents oxygen or sulfur, as well as their addition salts. The compounds of general formula (I) are active principles of antibacterial drugs.

Description

NOUVELLES QUINOLONES NEW QUINOLONES
LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONSTHEIR PREPARATION PROCESS AND THE COMPOSITIONS
PHARMACEUTIQUES EN RENFERMANTPHARMACEUTICALS CONTAINING
La présente invention a pour objet de nouvelles quinolones et plus particulièrement des quinolones substitués par un cycle pipéridinique.The subject of the present invention is new quinolones and more particularly quinolones substituted by a piperidine cycle.
Elle a plus particulièrement pour objet de nouveaux acides pipéridinyl quinolone 3-carboxyIiques doués de propriété antibactériennes intéressantes.It more particularly relates to new piperidinyl quinolone 3-carboxyIiques acids endowed with interesting antibacterial properties.
Elle a spécifiquement pour objet de nouveaux acides 6-fluoro 7- pipéridine quinoloneIt specifically relates to new acids 6-fluoro 7- piperidine quinolone
dans laquelle Z représente un radical amino, et RI représente un radical ( alcoyle inférieu éventuellement hydroxylé), un radical acyle dérivé d'un acide organique carboxylique, d'un acide aicoyl carbonique, ou d'un acide alcoylsulfonique, ou un radical arylamino carbonyle de la forme : in which Z represents an amino radical, and RI represents a radical (lower alkyl optionally hydroxylated), an acyl radical derived from an organic carboxylic acid, from an aicoyl carbonic acid, or from an alkylsulphonic acid, or an arylamino carbonyl radical of shape :
X IIX II
Ar - NH - C -Ar - NH - C -
dans laquelle Ar représente un radical aromatique mono ou bicyclique, éventuellement substitué par un, deux ou trois substituants choisis parmi les alcoyle inférieur, les halogènes et le trifluoromethyle. et X représente de l'oxygène ou du soufre.in which Ar represents a mono or bicyclic aromatic radical, optionally substituted by one, two or three substituents chosen from lower alkyl, halogens and trifluoromethyl. and X represents oxygen or sulfur.
FEUILLE DE REMPLACEMENT Parmi les composés de l'invention, on distingue trois sous-groupesREPLACEMENT SHEET Among the compounds of the invention, there are three subgroups
- les dérivés aminés et aicoyl aminés de formule IA- the amino and aicoyl amino derivatives of formula IA
dans laquelle RI représente de l'hydrogène ou un radical alcoyle inférieur linéaire ou ramifié, éventuellement substitué par un hydroxyle.in which RI represents hydrogen or a linear or branched lower alkyl radical, optionally substituted by a hydroxyl.
- les dérivés acylaminés de formule IB- the acylamine derivatives of formula IB
dans laquelle Ac représente le reste d'un acide carboxylique aliphatique, aromatique ou cyclanique ayant de 1 à 10 atomes de carbone, le reste d'un acide alcoylcarbonique ou bien le reste d'un acide alcoylsulfonique éventuellement substitué par un hydroxyle ou un radical trifluoromethyle. in which Ac represents the remainder of an aliphatic, aromatic or cyclanic carboxylic acid having from 1 to 10 carbon atoms, the remainder of an alkylcarbonic acid or else the remainder of an alkylsulfonic acid optionally substituted by a hydroxyl or a trifluoromethyl radical .
- les dérivés- drifts
FEUILLE DE REMPLACEMENT dans laquelle X représente de l'oxygène ou du soufre.REPLACEMENT SHEET in which X represents oxygen or sulfur.
W est un groupe C-H ou NW is a C-H or N group
B est de l'hydrogène ou une structure aromatique à 5 ou 6 chainons.B is hydrogen or an aromatic structure with 5 or 6 links.
Z est de l'hydrogène, un radical alcoyle inférieur, un radical trifluoromethyle ou un halogène. et p est égal à 1,2 ou 3Z is hydrogen, a lower alkyl radical, a trifluoromethyl radical or a halogen. and p is 1.2 or 3
Parmi les composés de formule général I les composés pour lesquel ZRl est une fonction ureido sont ceux qui sont actuellement préférés.Among the compounds of general formula I, the compounds for which ZR1 is a ureido function are those which are currently preferred.
Les composés selon l'invention peuvent être salifiés par addition d'une base minérale ou organique. Les principaux sels utilisables sont ceux de métaux alcalins, de métaux alcalinoterreux, d'ammonium, de fer, d'aluminium, les sels d'alcoylamines, les sels d'hydroxyalcoylamines, les sels de phénylalcoylamines, les sels de pyridylalcoylamines, les sels de cyclanylamines, les sels de dicyclanylalcoylamines...The compounds according to the invention can be salified by adding a mineral or organic base. The main salts which can be used are those of alkali metals, alkaline earth metals, ammonium, iron, aluminum, the alkylamine salts, the hydroxyalkylamine salts, the phenylalkylamine salts, the pyridylalkylamine salts, the salts of cyclanylamines, dicyclanylalkoylamine salts ...
Parmi ces sels, les sels de sodium, de lithium, d'ammonium, de N.methylglucamine et de tromethanol sont ceux présentement préférés.Among these salts, the sodium, lithium, ammonium, N.methylglucamine and tromethanol salts are those presently preferred.
Ces dérivés peuvent également exister sous forme de N- oxydes dont la solubilité dans l'eau et les milieux biologiques est augmentée.These derivatives can also exist in the form of N-oxides whose solubility in water and biological media is increased.
Ces composés peuvent également être salifiés par un acide minéral ou organique fort lloorrssqquuee . R^,rreepprréésseennttee ddee ll''hhydrogène, un radical alcoyle inférieur ou un radical (hydroxyalcoyle) inférieur.These compounds can also be salified with a strong mineral or organic acid. R ^, rreepprréésseennttee ddee ll'hydrogen, a lower alkyl radical or a lower radical (hydroxyalkyl).
Les composés selon l'invention possèdent des propretés anti-bactériennes très marquées, notamment contre les bactéries Gram positif.The compounds according to the invention have very marked anti-bacterial properties, in particular against Gram positive bacteria.
Ils possèdent en outre la propriété d'être très peu résorbés par voie digestive de sorte que leur élimination est essentiellement fécale.They also have the property of being very little absorbed by the digestive tract so that their elimination is essentially fecal.
FEUILLE DE REMPLACEMENT Ils peuvent donc être utilisés efficacement comme médicaments des infections bactériennes du tube digestif pour le traitement de la dyseπtrie bactérienne, de la diarrhée des voyageurs, ou des infection intestinales. Ils peuvent également servire par voie topique pour le traitement des infections oculaires ou des infections du conduit auditif.REPLACEMENT SHEET They can therefore be used effectively as drugs for bacterial infections of the digestive tract for the treatment of bacterial dysentry, travelers' diarrhea, or intestinal infections. They can also be used topically for the treatment of eye infections or ear canal infections.
A cette fin, les composés selon l'invention seront utilisés sous forme de compositions pharmaceutiques dans lesquelles le principe actif de formule générale I ou un de ses sels, est additionné ou mélangé avec un excipient ou un véhicule inerte non-toxique pharmaceutiquement acceptable.To this end, the compounds according to the invention will be used in the form of pharmaceutical compositions in which the active principle of general formula I or one of its salts, is added or mixed with an excipient or an inert non-toxic pharmaceutically acceptable vehicle.
Les formes pharmaceutiques les plus appropriées sont celles destinées à l'administration par voie digestive comme les solutés ou suspensions buvables, les granulés, les gélules, les comprimés nus ou enrobés, les dragés,les sachets de poudres aromatisés ou non, édulcorés ou non, les pilules ou les cachets. On peut également utiliser des solutions, des crèmes, des pommades, des sels pour l'application topique en tant qu' agent antibactérien externe.The most suitable pharmaceutical forms are those intended for administration by the digestive route such as oral solutions or suspensions, granules, capsules, bare or coated tablets, sugar-coated tablets, sachets of powdered flavored or not, sweetened or not, pills or cachets. Solutions, creams, ointments, salts can also be used for topical application as an external antibacterial agent.
La posologie moyenne dépend principalement de la sévérité de l'infection et de la sensibilité du germe microbien à l'agent antibactérien. La posologie unitaire s'échelonne de 100 à 600 mg par prise. La posologie journalière s'échelonne de 200 à 1200 mg répartie en 2 à 4 prises.The average dosage depends mainly on the severity of the infection and the sensitivity of the microbial germ to the antibacterial agent. The unit dosage ranges from 100 to 600 mg per dose. The daily dosage ranges from 200 to 1200 mg divided into 2 to 4 doses.
L'invention concerne également un procédé d'obtention des composés de formule générale I qui consiste en ce que l'on fait réagir l'acide 6-fluoro 7-jchloro 1-ethyl 4-oxo 1 ,4-dihydroquinoleine 3-carboxylique de formule II,The invention also relates to a process for obtaining the compounds of general formula I which consists in reacting 6-fluoro 7-jchloro 1-ethyl 4-oxo 1, 4-dihydroquinoleine 3-carboxylic acid. formula II,
FEUILLE DE REMPLACEMENT avec la 4-aminomethylpiperidine en milieu basique pour former un acide 6-fluoro 7-(4-aminomethylpiperidinyl- l) 4-oxo 1-ethyl 1,4-dihydroquinoleine 3-carboxylique de formule IIIREPLACEMENT SHEET with 4-aminomethylpiperidine in basic medium to form a 6-fluoro 7- (4-aminomethylpiperidinyl- l) 4-oxo 1-ethyl 1,4-dihydroquinoleine 3-carboxylic acid of formula III
que l'on peut si désiré : that we can if desired:
- salifier par addition d'une base minérale ou organique,- salify by adding a mineral or organic base,
- convertir en sel d'addition par adjonction d'un acide minéral ou organique,- convert to addition salt by adding a mineral or organic acid,
- N-oxyder par action d'un hydroperoxyde minéral ou organique,- N-oxidize by the action of a mineral or organic hydroperoxide,
- alcoyler par action d'un halogenure d'alcoyle en milieu basique.- alkylate by action of an alkyl halide in basic medium.
ou acyler par réaction avec un dérivé fonctionnel d'acide carboxylique ou sulfonique ou bien encore, avec un halogenoformiate d'alcoyle.or acylate by reaction with a functional derivative of carboxylic or sulfonic acid or alternatively, with an alkyl halogenoformate.
L'invention concerne aussi un procédé pour convertir le composé aminé de formule III en urée ou thiourée qui consiste à soumettre le composé de formule NI à l'action d'un isocyanate ou isothiocyanate d'aryle de formuleThe invention also relates to a process for converting the amino compound of formula III into urea or thiourea which consists in subjecting the compound of formula NI to the action of an isocyanate or aryl isothiocyanate of formula
Ar - N = C = XAr - N = C = X
dans laquelle Ar et X ont les définitions fournies précédemment.in which Ar and X have the definitions provided above.
FEUILLE DE REMPLACEMENT en solution dans un solvant inerte, pour obtenir le dérivé ureidique de formule IV.REPLACEMENT SHEET in solution in an inert solvent, to obtain the ureidic derivative of formula IV.
dans laquelle X et Ar sont définis comme précédemment. in which X and Ar are defined as above.
Les exemples suivants illustrent l'invention sans toutefois la limiter.The following examples illustrate the invention without, however, limiting it.
Exemple IExample I
Acide 6-fluoro 7-(4-aminomethylpiperidinyl-l) l-ethyl 4-oxo 1,4-dihydroquinoleinyl 3-carboxylique.6-fluoro 7- (4-aminomethylpiperidinyl-l) l-ethyl 4-oxo 1,4-dihydroquinoleinyl 3-carboxylic acid.
On chauffe 24 heures au reflux une solution de 5,39g (0.02M) d'acide 6 fluoro 7-chloro 1-ethyl 4-oxo 1,4-dihydroquinoleine 3-carboxylique et de 3,71 g (0,03M) de 4-aminomethylpiperidine dans 50 ml de pyridine.A solution of 5.39 g (0.02M) of 6 fluoro 7-chloro 1-ethyl 4-oxo 1,4-dihydroquinoleine 3-carboxylic acid and 3.71 g (0.03M) of 4-aminomethylpiperidine in 50 ml of pyridine.
Au bout de cette période de chauffage, on sépare les cristaux formés que l'on essore et que l'on fait cristalliser d'un mélange dimethylfor arnide-ethanol.At the end of this heating period, the crystals formed are separated, which are drained and which are crystallized from a mixture of dimethylfor arnide-ethanol.
On recueille ainsi 4,25 g de cristaux de couleur jaune pâle fondant (au bloc Koffler) à 190°.4.25 g of pale yellow crystals are thus collected, melting (at the Koffler block) at 190 °.
Le spectre IR et la micro-analyse sont en accord avec un produit solvaté avec 1,5 mol d'eau.The IR spectrum and the micro-analysis are in agreement with a product solvated with 1.5 mol of water.
FEUILLE DE REMPLACEMENT Par recristallisation du dimethylformamide ou recueille 3,65 g de cristaux jaune-pâleREPLACEMENT SHEET By recrystallization from dimethylformamide or collects 3.65 g of pale yellow crystals
(Rdt 52 %) fondant à 192°C. Spectre IR(Yield 52%) melting at 192 ° C. IR spectrum
CO 3400 cm " 1 CO 3400 cm "1
Micro-analyse calculée pour un produit à 1,5 mol d'eauMicro-analysis calculated for a product containing 1.5 mol of water
C H FN 0 + 3/2 H 0 = 374.40 _U5 3 3 -dC H FN 0 + 3/2 H 0 = 374.40 _U5 3 3 -d
Acide 7-[4(phenylamino carbonyl amino methyl) piperidinyl-l]6-fluoro 1-ethyl 4-oxo 1,4 dihydroquinoleinyl 3- carboxylique.7- [4 (phenylamino carbonyl amino methyl) piperidinyl-l] 6-fluoro 1-ethyl 4-oxo 1,4 dihydroquinoleinyl 3-carboxylic acid.
On dissout 3,47 g (0,01M) d'acide 7-(4-aminomethyl piperidinyl-1) 6-fluoro 1-ethyl 4-oxo l,4-dihydroquinoleinyl-3 carboxylique dans 30 ml de dimethylformamide et additionne la solution rapidement, sous agitation, de 3ml d'isocyanate de phenyle soit 3,28 g.3.47 g (0.01M) of 7- (4-aminomethyl piperidinyl-1) 6-fluoro 1-ethyl 4-oxo 1,4-dihydroquinoleinyl-3-carboxylic acid are dissolved in 30 ml of dimethylformamide and the solution is added. quickly, with stirring, 3 ml of phenyl isocyanate, ie 3.28 g.
On chauffe ensuite à 120°C pendant 3 heures et laisse reposer une nuit.Then heated to 120 ° C for 3 hours and allowed to stand overnight.
On essore les cristaux formés puis on les recristallise dans du methylformamide puis les lave à l'alcool. On recueille ainsi 2,07 g de cristaux incolores (Rdt 45 %) fondant au- dessus de 260°C.The crystals formed are drained and then recrystallized from methylformamide and then washed with alcohol. 2.07 g of colorless crystals are thus collected (yield 45%), melting above 260 ° C.
Spectre IR : CO à 1735 cm" 1 IR spectrum: CO at 1735 cm "1
CO du NH et Carbonyle à 1630 cm" 1.CO of NH and Carbonyl at 1630 cm "1 .
FEUILLE DE REMPLACEMENT . nalyse centésimale C2g H,--, FN^ Og = 466 , 56REPLACEMENT SHEET . centesimal analysis C2g H, -, FN ^ Og = 466, 56
De la même façon, on a préparé :In the same way, we prepared:
- la p. methylphenylurée F = 247'- p. methylphenylurea F = 247 '
- la m. fluoropheπylurée F = 258 - la 3,4 dichlorophenylurée F = 255- the m. fluoropheπylurée F = 258 - 3,4 dichlorophenyluré F = 255
- la p. ethoxycarbonyl phenylurée F = 239- p. ethoxycarbonyl phenylurea F = 239
- la p. methoxyphenylurée F = 241- p. methoxyphenylurea F = 241
- la p. nitrophenylurée F = 254- p. nitrophenylurea F = 254
- la 2,4 difluorophenylurée F = 241 - la 2-fluorophenyIurée F = 235- 2,4 difluorophenylurea F = 241 - 2-fluorophenylurea F = 235
- la naphtyl-1 thiourée F ≈ 260°- naphthyl-1 thiourea F ≈ 260 °
- La naphtyl-1 urée F = 255°- Naphtyl-1 urea F = 255 °
- la m. methoxyphenylurée F = 244°- the m. methoxyphenylurea F = 244 °
- la 3,4-dichlorophenylthiourée F = 258°- 3,4-dichlorophenylthiourea F = 258 °
Essais bactériologiques des composés selon l'invention : I MATERIEL ET METHODESBacteriological tests of the compounds according to the invention: I MATERIAL AND METHODS
1) Dans un premier temps de criblage, les produits ont été testés vis-à-vis de 6 souches de référence : 3 espèces à gram positif :1) In a first screening phase, the products were tested against 6 reference strains: 3 species with a positive gram:
- Bacillus subtilis ATCC 93722 - Staphylococcus aureus ATCC 25923- Bacillus subtilis ATCC 93722 - Staphylococcus aureus ATCC 25923
- Streptococcus faecalis ATCC 8043- Streptococcus faecalis ATCC 8043
3 espèces à gram négatif :3 gram negative species:
- Escherichia coli ATCC 25922- Escherichia coli ATCC 25922
- Pseudomoπas aeruginosa ATCC 22853 - Acinetobacter calcoaceticus variété anitratum ATCC 17903- Pseudomoπas aeruginosa ATCC 22853 - Acinetobacter calcoaceticus variety anitratum ATCC 17903
FEUILLE DE REMPLACEMENT 2) La mesure des concentrations minimales inhibitrices a été faite par une technique de microdilution en milieu liquide (bouillon de Mueller-Hinton) sous un volume de 100 μl et pour une gamme de concentration allant de 128 à 0,06 mg L, préparée à partir d'une solution-mère d'antibiotique titrant 512 mg/L. La préparation de ces solutions-mères effectuée selon les directives du fabricant a varié selon les molécules.REPLACEMENT SHEET 2) The measurement of the minimum inhibitory concentrations was made by a microdilution technique in liquid medium (Mueller-Hinton broth) in a volume of 100 μl and for a concentration range from 128 to 0.06 mg L, prepared at from a stock solution of antibiotic titrated 512 mg / L. The preparation of these stock solutions carried out according to the manufacturer's instructions varied according to the molecules.
L'inoculation se fait en ajoutant dans chaque capsule 10 μl d'une dilution en eau physiologique d'un bouillon de 18 H en bouillon coeur cervelle telle que chaque cupule contienne environ 10 bactéries/ml.The inoculation is done by adding to each capsule 10 μl of a dilution in physiological water of an 18 H broth in brain heart broth such that each cup contains approximately 10 bacteria / ml.
La concentration minimale inhibitrice est lue comme la première concentration d'antibiotique ne donnant pas de culture, macroscopiquement visible après 18 H d'incubation à 37°. La concentration minimale bactéricide (CMB) est la première concentration pour laquelle l'effet bactéricide •$ 0,01 de germes survivants a été obtenue.The minimum inhibitory concentration is read as the first concentration of non-culture-giving antibiotic, macroscopically visible after 18 H of incubation at 37 °. The minimum bactericidal concentration (CMB) is the first concentration for which the bactericidal effect • $ 0.01 of surviving germs was obtained.
II RESULTATSII RESULTS
Le composé de l'exemple II a été trouvé le plus actif. En particulier vis-à-vis de Staphycocoque aureus :The compound of Example II was found to be the most active. In particular with regard to Staphycococcus aureus:
la CMI est de 0,2 mcg/ml la CMB est de 0,5 mcg/ml.the MIC is 0.2 mcg / ml the CMB is 0.5 mcg / ml.
vis-à-vis d'Escherichia colivis-à-vis Escherichia coli
la CMI est de 8 mcg/ml la CMB est de 8 mcg/mlthe MIC is 8 mcg / ml the CMB is 8 mcg / ml
microplaques et inoculateur DynatechDynatech microplates and inoculator
FEUILLE DE REMPLACEMENT REPLACEMENT SHEET

Claims

REVEND1CATIONS
L'invention a pour objet :The subject of the invention is:
1°) De nouveaux acides 6-fluoro 7-piperidine quinoleine 3-carboxylique choisis dans le groupe constitué par a) les composés de formule I1 °) New 6-fluoro 7-piperidine quinoleine 3-carboxylic acids chosen from the group consisting of a) the compounds of formula I
dans laquelle Z représente un radical amino, et j un radical (aicoyl inférieur éventuellement hydroxyle), un radical acyle dérivé d'un acide organique carboxylique, d'un acide aicoyl carbonique, ou d'un acide alcoylsulfonique, ou un radical arylamino carbonyle de la forme : in which Z represents an amino radical, and j a radical (lower aicoyl optionally hydroxyl), an acyl radical derived from an organic carboxylic acid, an aicoyl carbonic acid, or an alkylsulfonic acid, or an arylamino carbonyl radical of the form :
X Ar - NH - C - dans laquelle Ar représente un radical aromatique, mono ou bicyclique, éventuellement substitué par un, deux ou trois substituants choisis parmi les alcoyle inférieur, les halogènes et le trifluoromethyle. et X représente de l'oxygène ou du soufre. R représente un oxygène lié par une valence semi-polaire, et n est égal à zéro ou un. et les composés répondant à la formule 1^X Ar - NH - C - in which Ar represents an aromatic radical, mono or bicyclic, optionally substituted by one, two or three substituents chosen from lower alkyl, halogens and trifluoromethyl. and X represents oxygen or sulfur. R represents oxygen bound by a semi-polar valence, and n is zero or one. and the compounds corresponding to formula 1 ^
dans laquelle Ri représente de l'hydrogène, ou un radical alcoyle inférieur, linéaire ou ramifié éventuellement substitué par un hydroxyle. in which R 1 represents hydrogen, or a lower, linear or branched alkyl radical optionally substituted by a hydroxyl.
FEUILLE DE REMPLACEMENT - 1 1REPLACEMENT SHEET - 1 1
2°) Un composé selon la revendication 1 ° répondant à la formule générale IB :2 °) A compound according to claim 1 ° corresponding to the general formula IB:
NH ACNH AC
dans laquelle Ac représente le reste d'un acide carboxylique aliphatique, aromatique ou cyclanique ayant de 1 à 10 atomes de carbone, le reste d'un acide alcoylcarbonique ou bien le reste d'un acide alcoylsulfonique éventuellement substitué par un hydroxyle ou un radical trifluoromethyle.in which Ac represents the remainder of an aliphatic, aromatic or cyclanic carboxylic acid having from 1 to 10 carbon atoms, the remainder of an alkylcarbonic acid or else the remainder of an alkylsulfonic acid optionally substituted by a hydroxyl or a trifluoromethyl radical .
3°) Un composé selon la revendication Ie répondant à la formule IC :3 °) A compound according to claim I e corresponding to formula IC:
BB
dans laquelle X représente de l'oxygène ou du soufre.in which X represents oxygen or sulfur.
W est un groupe C-H ou ^.NW is a C-H or ^ .N group
B est de l'hydrogène ou une structure aromatique à 5 ou 6 chaînons.B is hydrogen or a 5 or 6-membered aromatic structure.
Z est de l'hydrogène, un radical alcoyle inférieur, un radical trifluoromethyle ou un halogène. et est égal à 1, 2 ou 3.Z is hydrogen, a lower alkyl radical, a trifluoromethyl radical or a halogen. and is equal to 1, 2 or 3.
FEUILLE DE REMPLACEMENT 4°) Les sels des composés selon l'une des revendications 1° à 4° avec une base minérale ou organique.REPLACEMENT SHEET 4 °) The salts of the compounds according to one of claims 1 ° to 4 ° with a mineral or organic base.
5°) Les sels des composés selon la revendication 1° avec un acide minéral ou organique fort, lorsque Rj représente de l'hydrogène, un radical alcoyle inférieur ou un radical (hydroxyalcoyle inférieur).5 °) The salts of the compounds according to claim 1 ° with a strong mineral or organic acid, when R j represents hydrogen, a lower alkyl radical or a radical (lower hydroxyalkyl).
6°) Les compositions pharmaceutiques dans lesquelles au moins un composé de formule générale I ou un des sels, selon la revendication l° est additionné ou mélangé à un excipient ou véhicule inerte, non toxique, pharmaceutiquement acceptable.6 °) The pharmaceutical compositions in which at least one compound of general formula I or one of the salts, according to claim 1 ° is added or mixed with an inert excipient or vehicle, non-toxic, pharmaceutically acceptable.
7°) Une composition pharmaceutique selon la revendication dans laquelle le véhicule ou l'excipient est un de ceux qui conviennent pour l'administration par voie digestive.7 °) A pharmaceutical composition according to claim in which the vehicle or the excipient is one of those which are suitable for the administration by digestive route.
8°) Une composition pharmaceutique selon la revendication 7° dans laquelle le véhicule ou l'excipient est un de ceux qui conviennent pour l'application topique.8 °) A pharmaceutical composition according to claim 7 ° wherein the vehicle or the excipient is one of those which are suitable for the topical application.
9°) Une composition pharmaceutique selon la revendication 7° dans laquelle la teneur en principe selon la revendication Ie s'échelonne de 100 à 600 mg par prise unitaire.9 °) A pharmaceutical composition according to claim 7 in which the content in principle according to claim I e ranges from 100 to 600 mg per unit dose.
10°) Un procédé d'obtention des composés de formule générale 1 selon la revendication 1° qui consiste en ce que l'on fait réagir l'acide 6-fluoro 7-chloro 1-ethyl 4-oxo 1,4-dihydroquinoleine 3-carboxylique de formule II.10 °) A process for obtaining the compounds of general formula 1 according to claim 1 which consists in reacting 6-fluoro 7-chloro 1-ethyl 4-oxo 1,4-dihydroquinoleine 3 -carboxylic of formula II.
FEUILLE DE REMPLACEMENT avec la 4-aminomethylpiperidiπe en milieu basique pour former un acide 6-fluoro 7-(4-aminomethylpiperidinyl-l) 4-oxo 1-ethyl 1,4-dihydroquinoleine 3-carboxylique de formule III 0REPLACEMENT SHEET with 4-aminomethylpiperidiπe in basic medium to form a 6-fluoro 7- (4-aminomethylpiperidinyl-l) 4-oxo 1-ethyl 1,4-dihydroquinoleine 3-carboxylic acid of formula III 0
- salifier par addition d'une base minérale ou organique,- salify by adding a mineral or organic base,
<-, - convenir en sel d'addition par adjonction d'un acide minéral ou organique,<-, - be suitable as an addition salt by adding a mineral or organic acid,
- N-oxyder par action d'un hydroperoxyde minéral ou organique,- N-oxidize by the action of a mineral or organic hydroperoxide,
- ou acyler par réaction avec un dérivé fonctionnel d'acide carboxylique ou sulfonique ou bien encore, avec un halogenoformiate d'alcoyle.- Or acylate by reaction with a functional derivative of carboxylic or sulfonic acid or alternatively, with an alkyl halogenoformate.
12°) Un procédé d'obtention des composés de formule générale (le) selon la 0 revendication 1° ou la revendication 4° qui consiste en ce que l'on soumet un composé de formule III12 °) A process for obtaining the compounds of general formula (Ie) according to claim 1 ° or claim 4 ° which consists in subjecting a compound of formula III
00
à l'action d'un isocyanate ou isothiocyanate d'aryle de formule générale to the action of an aryl isocyanate or isothiocyanate of general formula
Ar - N = C = XAr - N = C = X
FEUILLE DE REMPLACEMENT dans laquelle Ar et X ont les définitions fournies précédemment.REPLACEMENT SHEET in which Ar and X have the definitions provided above.
en solution dans un solvant inerte, pour obtenir le dérivé ureidique de formule généralein solution in an inert solvent, to obtain the ureidic derivative of general formula
dans laquelle X et Ar sont définis comme précédemment. in which X and Ar are defined as above.
FEUILLE DE REMPLACEMENT REPLACEMENT SHEET
EP19920909453 1991-04-04 1992-04-06 Novel quinolones, method of preparation and pharmaceutical compositions containing them Withdrawn EP0533895A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9104227A FR2674854B1 (en) 1991-04-04 1991-04-04 NEW QUINOLONES THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS THEREOF.
FR9104227 1991-04-04

Publications (1)

Publication Number Publication Date
EP0533895A1 true EP0533895A1 (en) 1993-03-31

Family

ID=9411569

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920909453 Withdrawn EP0533895A1 (en) 1991-04-04 1992-04-06 Novel quinolones, method of preparation and pharmaceutical compositions containing them

Country Status (3)

Country Link
EP (1) EP0533895A1 (en)
FR (1) FR2674854B1 (en)
WO (1) WO1992017466A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904108D0 (en) * 1999-11-15 1999-11-15 New Pharma Research Ab New compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814517A1 (en) * 1988-02-05 1989-08-17 Bayer Ag CHINOLON AND NAPHTHYRIDONE CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THE SAME
CA1340285C (en) * 1988-05-19 1998-12-22 Hiroyuki Nagano Novel quinolonecarboxylic acid derivatives having at 7-position a piperidin-1-yl substituent
JPH0348678A (en) * 1989-07-14 1991-03-01 Chugai Pharmaceut Co Ltd Novel quinolone-based antimicrobial agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9217466A1 *

Also Published As

Publication number Publication date
FR2674854A1 (en) 1992-10-09
FR2674854B1 (en) 1995-03-03
WO1992017466A1 (en) 1992-10-15

Similar Documents

Publication Publication Date Title
FR2671800A1 (en) OPTICALLY ACTIVE 5H-PYRROLO [3,4-B] PYRAZINE DERIVATIVE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
EP0799833A1 (en) Erythromycin derivatives, their production and their use as medicaments
FR2493322A1 (en) CRYSTALLINE HYDRATES OF DIOXO-1,1 PENICILLANOYLOXYMETHYL (D-A-AMINO A-PHENYLACETAMIDO) -6 PENICILLANATE USEFUL AS ANTIMICROBIAL MEDICAMENTS AND METHODS OF THEIR PREPARATION
US11292794B2 (en) 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same
EP0067772B1 (en) N-dihydrothiazolyl-3-quinoleine carboxyamide derivatives, their salts, their preparation and use as pharmaceutical preparations, and pharmaceutical preparations containing them
EP0134165B1 (en) 7-(pyrrol-1-yl)-1-ethyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid and 7-(pyrrol-1-yl)-1-ethyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives, their preparation and use as medicaments
CH633556A5 (en) THERAPEUTICALLY ACTIVE AMIDES AND METHODS FOR PRODUCING THE SAME.
CN104788473A (en) Antibacterial compound as well as preparation method and application thereof
EP0533895A1 (en) Novel quinolones, method of preparation and pharmaceutical compositions containing them
JPS60126284A (en) Pyridonecarboxylic acid derivative and salt thereof
EP0535184A1 (en) Novel quinolones, process for their preparation and pharmaceutical compositions containing same
FR2645862A1 (en) SUBSTITUTED ISOTHIAZOLO-PYRYDONE AZETIDINYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
CN104804019B (en) Compound with antibacterial ability as well as preparation method and application thereof
EP0598089A1 (en) Novel fluorinated quinolones, process for their preparation and pharmaceutical preparations containing same
FR2706459A1 (en) New quinolone derivatives, a process for their preparation and the pharmaceutical compositions which contain them
EP0530355A1 (en) Novel fluorine-containing quinolones and process for their preparation
CN116768813B (en) Pleuromutilin derivatives, uses and pharmaceutical compositions thereof
CA1093582A (en) Process for the preparation of propylenediamines
FR2694751A1 (en) Novel sulfonamide derivatives, processes for their preparation and compositions containing them
EP4104902A1 (en) Compound and drug containing same
US3682956A (en) Substituted 3-(5-nitro-2-furyl)-pyrazoles
US4091094A (en) 9-Azariboflavin and pharmaceutical composition containing same
US4889874A (en) Hydroxamic acid derivatives and method of using same
JP2023084946A (en) Novel compound having bioactivity
FR2534254A1 (en) NEW DERIVATIVE OF SULPIRIDE, METHOD FOR OBTAINING SAME AND THERAPEUTIC USE THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19930512

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19951102